Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Oncternal Goes Public Via Reverse Merger With GTx

Executive Summary

All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.

You may also be interested in...



Mehta Analysis: BMS/Celgene Merger Shows Big Pharma Is Stuck In Wrong Groove

Bristol-Myers Squibb executives are justifying the acquisition of Celgene in terms that have been well-rehearsed through the history of big pharma mergers. But they are failing to consider radical changes to the environment in which pharma operates, argues Viren Mehta of Mehta Partners LLC.

Shionogi Builds Digital Therapeutics Presence Through Akili Alliance

Shionogi has become the latest Japanese company to build its presence in the digital health realm, this time through an alliance with Akili for two novel digital therapeutics.

Pro Vs. Con: A Side-By-Side Look At Investor Concerns, Bristol's Defenses Of Celgene Deal

Activist investors continue to question the value of Bristol-Myers Squibbs' acquisition of Celgene ahead of an April 12 shareholder vote on the deal, but Bristol released a new overview of the transaction to rebut arguments against it.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC124890

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel